Jun 01, 2022
|
HOUSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development
|
|
May 26, 2022
|
HOUSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a Trials in Progress poster presentation at the 2022 American Society of Clinical Oncology Annual Meeting being
|
|
May 16, 2022
|
Successfully dosed first patient in TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications Will present preclinical data today at the ASGCT 25 th Annual Meeting highlighting the potential of mbIL-15 as a potent and more durable TCR-T cell therapy
|
|
May 10, 2022
|
HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development
|
|
May 09, 2022
|
HOUSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the first quarter ended March 31, 2022 on Monday, May 16, 2022, before the open of U.S. markets.
|
|
May 02, 2022
|
Preclinical data to be presented highlights the potential ability to generate mbIL-15 TCR-T cells targeting hotspot mutations expressed in solid tumors with enhanced survival capacity HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a
|
|
May 02, 2022
|
First-in-human non-viral TCR-T cell therapy targeting shared hotspot mutations in solid cancers First clinical product manufactured and administered to a patient using the Company’s in house cGMP manufacturing facility Expect to report initial data in 2H22 HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) --
|
|
Mar 30, 2022
|
Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; first patient consented and is expected to dose in 2Q 2022 Extended CRADA with the National Cancer Institute focused on evaluating Alaunos’ TCR-T Library in a personalized TCR-T program The
|
|
Mar 16, 2022
|
HOUSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the fourth quarter ended December 31, 2021 on Wednesday, March 30, 2022, before the open of U.S. markets.
|
|
Mar 08, 2022
|
HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that the Company’s Chief Executive Officer, Kevin S. Boyle Sr., and Vice President of Research & Development,
|
|